The Australian Government has listed a range of medicines for treating multiple sclerosis, asthma and diabetes on the Pharmaceutical Benefits Scheme (PBS). The listings will provide valuable support for more than 51,800 Australians living with these conditions, saving them up to $29,000 a year.
The Government has added a life-changing new eczema medicine to the Pharmaceutical Benefits Scheme (PBS). The $270 million in funding to list the medicine will help up to 3,600 Australians over 12 years of age living with severe eczema.
The Government will invest $47 million over 4 years into a program to accelerate cutting-edge research into two of the most prominent health conditions that affect millions of Australians – diabetes and cardiovascular disease.
The Australian Government, together with the National Heart Foundation, has announced a further $12 million for research to improve treatment of people, including children, suffering cardiovascular disease and stroke.
The Australian Government is investing in vital research initiatives to tackle the nation’s two biggest killers — heart disease and stroke. This funding is the first round of disbursements from the Medical Research Future Fund’s (MRFF) Cardiovascular Health Mission.
More than one year on from the first ever National Action Plan for Endometriosis, the Australian Government is continuing to support women and girls with endometriosis.
A new online directory will provide people living with chronic pain—and their health practitioners—with a comprehensive list of available services to help manage their conditions.
The Australian Government is calling for proposals for $3 million in research to better understand the causes and improve diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).
The ABS’ Causes of Death, Australia, 2018 report notes suicide dropped one place to 14th leading cause of death overall. Rates of mortality due to heart disease and cerebrovascular disease also decreased, however these remain among the leading causes of death in Australia.
The Australian Government will invest over $40 million to provide affordable access to 2 new medicine listings through the Pharmaceutical Benefits Scheme (PBS). This will help Australians with opiate addiction and those suffering breathlessness throughout their final stages of life.
The Australian Government Department of Health has established a National Dust Disease Taskforce to develop a national approach to the prevention, early identification, control and management of dust diseases in Australia.
The Australian Government is expanding access to a critically important medicine on the Pharmaceutical Benefits Scheme (PBS) that will help infants living with Cystic Fibrosis and save their families up to $300,000 per year.
November is Lung Cancer Awareness Month and from 1 November, Keytruda® will be listed on the PBS for first-line treatment of people with metastatic non-small cell lung cancer.